- Home
- CET vs KOD Comparison
CET vs KOD Comparison
Compare CET & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CET | KOD |
|---|---|---|
| Founded | 1929 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | CET | KOD |
|---|---|---|
| Price | $49.73 | $21.69 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $28.29 |
| AVG Volume (30 Days) | 39.6K | ★ 438.3K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 5.47% | N/A |
| EPS Growth | N/A | ★ 32.60 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.93 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $40.24 | $1.92 |
| 52 Week High | $52.95 | $31.18 |
Technical Indicators
Market Signals| Indicator | CET | KOD |
|---|---|---|
| Relative Strength Index (RSI) | 41.35 | 38.92 |
| Support Level | $49.88 | $21.19 |
| Resistance Level | $51.26 | $29.17 |
| Average True Range (ATR) | 1.02 | 1.54 |
| MACD | -0.11 | -0.34 |
| Stochastic Oscillator | 26.21 | 14.55 |
Price Performance
Historical ComparisonAbout CET Central Securities Corporation
Central Securities Corp is a non-diversified closed-end management investment company. Its investment objective is long-term growth of capital. The company invests in common stocks, bonds, convertible bonds, preferred stocks, convertible preferred stocks, warrants, options real estate, or short-term obligations of governments, banks, and corporations.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.